Epizyme, a biotechnology start up based in Cambridge, Mass. has inked a deal with GlaxoSmithKline worth up to $650 million. The collaboration will focus on discovering, developing and marketing drugs to treat cancer and other diseases using Epizyme’s technology surrounding epigenetic enzymes, proteins which are thought to play a key role in turning genes on or off. The goal is to design personalized medicines for specific patient populations.
UK-based Glaxo will pay Cambridge, Mass.-based Epizyme $20 million in upfront payments. Epizyme is eligible to receive up to an additional $630 in milestone payments if the collaboration yields approved drugs.
via bizjournals.com
No comments:
Post a Comment